1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1345/aph.1M102" target="_blank" rel="noreferrer noopener">http://doi.org/10.1345/aph.1M102</a> Rights Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). Pages 1445-1455 Issue 9 Volume 43 Search for Full-text Locate full-text within NEOMED Library's e-journal collections <p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Denosumab in Osteoporosis and Oncology Publisher An entity responsible for making the resource available Annals of Pharmacotherapy Date A point or period of time associated with an event in the lifecycle of the resource 2009 2009-09 Subject The topic of the resource Prostate cancer; breast-cancer; osteoporosis; Pharmacology & Pharmacy; postmenopausal women; breast-cancer; bone-mineral density; tumor; metastases; ligand; biochemical markers; bisphosphonate therapy; bone metastases; denosumab; monoclonal antibody; multiple; myeloma; necrosis factor; phase-ii; RANKL; solid tumor; turnover; zoledronic acid Creator An entity primarily responsible for making the resource Burkiewicz J S; Scarpace S L; Bruce S P Description An account of the resource OBJECTIVE: To review the pharmacology, pharmacokinetics, pharmacodynamics, safety, efficacy, and use of denosumab in osteoporosis, breast cancer, prostate cancer, and multiple myeloma. DATA SOURCES: Studies and abstracts were identified through MEDLINE and International Pharmaceutical Abstracts (1966-July 2009). Key search terms include denosumab, AMG-162, and receptor activator of nuclear factor-kappa B ligand system. Information available in abstract form was retrieved from major oncology and bone metabolism meetings. Additional data were obtained from the manufacturer. STUDY SELECTION AND DATA EXTRACTION: All available studies in humans were included except for studies in rheumatoid arthritis and giant cell tumor of the bone. DATA SYNTHESIS: In patients with osteoporosis, denosumab significantly reduces bone resorption and fractures. Studies of denosumab in the prevention and treatment of osteoporosis have demonstrated significantly increased bone mineral density and reduced bone turnover markers. Studies of denosumab versus placebo in the treatment of osteoporosis have demonstrated reductions in vertebral, hip, and nonvertebral fractures. In oncology, positive results from clinical trials in patients receiving endocrine therapy for breast and prostate cancer demonstrated decreases in bone loss and skeletal-related events. Denosumab seems to be at least as effective in reducing bone turnover markers as intravenous bisphosphonates in the oncology setting. The most common adverse effects in patients with osteoporosis were arthralgia, nasopharyngitis, back pain, and headache. The most common adverse effects in patients with cancer were infection, pain in the extremities, arthralgia, bone pain, fatigue, and pain. Serious adverse effects include infections requiring hospitalization. CONCLUSIONS: Denosumab has documented efficacy and safety in patients with osteoporosis, breast cancer, and prostate cancer. Additional clinical trial data are needed to more completely establish the effectiveness of denosumab in the treatment of osteoporosis and neoplastic disease as well as its cost-effectiveness and long-term safety. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1345/aph.1M102" target="_blank" rel="noreferrer noopener">10.1345/aph.1M102</a> Format The file format, physical medium, or dimensions of the resource Journal Article or Conference Abstract Publication 2009 Annals of Pharmacotherapy biochemical markers bisphosphonate therapy Bone metastases bone-mineral density breast-cancer Bruce S P Burkiewicz J S denosumab Department of Pharmacy Practice Journal Article or Conference Abstract Publication ligand metastases monoclonal antibody Multiple myeloma necrosis factor NEOMED College of Pharmacy Osteoporosis Pharmacology & Pharmacy phase-ii postmenopausal women Prostate cancer RANKL Scarpace S L solid tumor Tumor Turnover zoledronic acid